Improving Outcomes in Ovarian Cancer

Improving Outcomes in Ovarian Cancer

Patients with newly diagnosed advanced ovarian cancer are treated with cytoreductive surgery and platinum-based chemotherapy. 70 percent of these patients go on to relapse within the next three years. Olaparib is a poly (adenosine diphosphate ribose) polymerase or PARP inhibitor that interferes with DNA repair, especially in tumors with BRCA1 or BRCA2 mutations. It’s approved […]

Continue reading


Targeting Epstein-Barr Virus–Associated Lymphomas

Targeting Epstein-Barr Virus–Associated Lymphomas

Targeting Epstein-Barr virus-associated lymphomas. During stimulation of naive B cells by antigen, a progression from activated B cell through the germinal center and differentiation to a memory B cell occurs. After Epstein-Barr virus (EBV) infection of a naive B cell, different programs of EBV-latent proteins are expressed that drive differentiation of the infected B cell […]

Continue reading